- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:08 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| Mi | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | VITA LIFE SCIENCES LIMITED: Employee Share Buy Back | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Notification of buy-back - VLS | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Notice of General Meeting/Proxy Form | - | ASX | ||
| Fr | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 21.04. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 20.04. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 07.04. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 30.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 29.03. | VITA LIFE SCIENCES LIMITED: AGM Date and Closing Date for Directors' Nomination | - | ASX | ||
| 27.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 26.03. | VITA LIFE SCIENCES LIMITED: App 4G Corporate Governance Statement | 1 | ASX | ||
| 26.03. | VITA LIFE SCIENCES LIMITED: Annual Report to shareholders | 2 | ASX | ||
| 24.03. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 19.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 17.03. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 15.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 12.03. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,630 | -2,07 % | Green Thumb Industries Inc: Green Thumb adds $100-million of share buyback capacity | ||
| ALNYLAM PHARMACEUTICALS | 256,00 | -0,81 % | Alnylam vor Quartalszahlen: Kann Wachstumstreiber Amvuttra das Momentum halten? | ||
| NEKTAR THERAPEUTICS | 70,60 | -1,34 % | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,346 | +0,75 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| ADASTRA | 0,089 | 0,00 % | Adastra Holdings Ltd.: Adastra Holdings Announces Resignation of Director | Langley, British Columbia--(Newsfile Corp. - April 29, 2026) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,020 | -3,37 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,375 | 0,00 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 24,100 | -4,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 68,00 | +0,74 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET | ||
| ZELIRA THERAPEUTICS | 0,300 | 0,00 % | ZELIRA THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | ||
| OPUS GENETICS | 4,160 | -2,80 % | Citizens initiates Opus Genetics stock coverage with outperform rating | ||
| SOLIGENIX | 0,337 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma | PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| SAVARA | 4,109 | -3,84 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| RESTART LIFE SCIENCES | 0,062 | +1,64 % | Restart Life Sciences Corp.: Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.